Research programme: VLA-4 antagonists - Biogen Idec

Drug Profile

Research programme: VLA-4 antagonists - Biogen Idec

Alternative Names: VLA-4 antagonists research programme - Biogen Idec

Latest Information Update: 04 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec
  • Class
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation; Multiple sclerosis

Most Recent Events

  • 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
  • 10 Jul 2002 This programme is still in active development
  • 12 Oct 1999 Preclinical development for Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top